Abstract: Compounds of formula (I), formula (I), processes for their production and their use as pharmaceuticals.

Abstract: Systems, methods, and computer programs for monitoring the disease progression of a Parkinson's patient are provided. Specifications for a Parkinson's patient may defined in a computer system by a physician. The specifications may contain threshold values. At repeating points in time, a message may including a request to perform a mobility test may be output by the computer system to the patient. Mobility parameters may be determined as a result of the performance of the mobility test. The mobility parameters may be compared with the threshold values to determine one or more deviations between the one or more mobility parameters and the one or more threshold values. The mobility parameters, the deviations, or a combination thereof may be made available to the physician by outputting or storing the mobility parameters or the deviations or by transmitting the mobility parameters or the deviations to a separate computer system.

Abstract: The present invention relates to compounds of formula (I) processes for their production and their use as pharmaceuticals. The compounds are inhibitors of Casein kinase 1 alpha and/or delta (CSNK1? and/or ?) useful for the treatment of proliferative disorders.

Abstract: Compounds of formula (I), processes for their production and their use as pharmaceuticals are described herein.

Abstract: The present invention covers phosphorus derivatives of general formula (I), in which R1, R2, R3, R4, R5, R6, X1, X2, X3, X4 and Y are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, especially diseases associated with SOS1, as a sole agent or in combination with other active ingredients.

Abstract: The present invention describes 2-methyl-quinazoline compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions. The 2-methyl substituted quinazoline compounds of general formula (I) effectively and selectively inhibit the Ras-Sos interaction without significantly targeting the EGFR receptor. They are therefore useful for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, such as cancer as a sole agent or in combination with other active ingredients.

Abstract: Compounds of formula (I) processes for their production and their use as pharmaceuticals.

Abstract: The invention relates to an apparatus for the single-track or multi-track conveying of objects along a conveying path extending in a conveying direction, wherein the conveying path for at least one track comprises at least one conveying device that takes over objects at the input side from a functional unit connected upstream and that transfers objects at the output side to a functional unit connected downstream; and wherein the conveying device as a whole and/or in an output-side end region is adjustable transversely to the conveying direction by means of an adjustment device such that the transverse position of objects to be transferred is changed within the respective track.

Abstract: Compounds of formula (I) processes for their production and their use as pharmaceuticals.

Abstract: Compounds of formula (I) for use in the treatment or prophylaxis of a disease, which is a hyperproliferative disease and/or a disorder responsive to induction of cell death, selected from a haematological tumour, a solid tumour and/or metastases thereof, said tumour harbouring a mutant EGFR with exon 19 or 21 mutations, and their use as pharmaceuticals.

Abstract: Compounds of formula (I), formula (I), processes for their production and their R use as pharmaceuticals.

Abstract: The present invention covers 2-methyl-aza-quinazoline compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients

Abstract: The present invention describes 2-methyl-quinazoline compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions. The 2-methyl substituted quinazoline compounds of general formula (I) effectively and selectively inhibit the Ras-Sos interaction without significantly targeting the EGFR receptor. They are therefore useful for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, such as cancer as a sole agent or in combination with other active ingredients.

Abstract: The present invention relates to compounds of formula (1) in which A, U and R1 are as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant KRAS signaling, as a sole agent or in combination with other active ingredients.

Abstract: A process for producing dimensionally stable food products continuously introduces food raw materials and water into the housing of an extruder. At least one screw is arranged in the housing. The screw is rotated to generate a mixture of the food raw materials in the housing. A section ahead of the outlet of the housing is controlled to heat the mixture to at least 60° C. to produce a cooked mass from the mixture. The cooked mass is discharged from the outlet and deposited on a carrier. The carrier is moved in a controlled manner relative to the outlet to produce form-stable food products on the carrier. The depositing of the cooked mass takes place in directly adjacent lanes into mass strips, which preferably lie in at least two planes on top of one another. .

Abstract: The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients.

Abstract: The invention relates to an apparatus for the single-track or multi-track conveying of objects along a conveying path extending in a conveying direction, wherein the conveying path for at least one track comprises at least one conveying device that takes over objects at the input side from a functional unit connected upstream and that transfers objects at the output side to a functional unit connected downstream; and wherein the conveying device as a whole and/or in an output-side end region is adjustable transversely to the conveying direction by means of an adjustment device such that the transverse position of objects to be transferred is changed within the respective track.

Abstract: The invention relates to a device for moving portions, which each comprise at least one slice cut from a food product, in particular by means of a slicing device, in particular a high-speed slicer, comprising a plurality of individually movable transport movers each for at least one portion, a track system for the transport movers, in which track system the transport movers can be moved along at least one specified track in a transport direction, and a control apparatus for controlling the movements of the transport movers in the track system, wherein the transport movers each comprise at least one runner that interacts with the track system and at least one carrier for at least one portion, the at least one carrier being attached to the runner by means of a retainer, and wherein the drive for each transport mover is formed by the runner and the track system, which together form an electromagnetic drive for the transport mover.

Abstract: Compounds of formula (I) which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals.

Abstract: Compounds of formula (I) as defined herein and their use as pharmaceuticals.